CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations

IF 6.4 2区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Mutation Research-Reviews in Mutation Research Pub Date : 2021-01-01 DOI:10.1016/j.mrrev.2021.108374

Mohammad Mahmoudi Gomari , Marziye Farsimadan , Neda Rostami , Zahra mahmoudi , Mahmood Fadaie , Ibrahim Farhani , Parastoo Tarighi

{"title":"CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations","authors":"Mohammad Mahmoudi Gomari , Marziye Farsimadan , Neda Rostami , Zahra mahmoudi , Mahmood Fadaie , Ibrahim Farhani , Parastoo Tarighi","doi":"10.1016/j.mrrev.2021.108374","DOIUrl":null,"url":null,"abstract":"<div><p>Among cell surface markers<span><span>, CD44 is considered the main marker for identifying and isolating the </span>cancer stem cells<span> (CSCs) among other cells and has attracted significant attention in a variety of research areas. Many studies have shown the essential roles of CD44 in initiation, metastasis, and tumorigenesis in different types of cancer; however, the validity of CD44 as a therapeutic or diagnostic target has not been fully confirmed in some other studies. Whereas the association of specific single nucleotide polymorphisms (SNPs) in the CD44 gene and related variants with cancer risk have been observed in clinical investigations, the significance of these findings remains controversial. Here, we aimed to provide an up-to-date overview of recent studies on the association of CD44 polymorphisms and its variants with different kinds of cancer to determine whether or not it can be used as an appropriate candidate for cancer tracking.</span></span></p></div>","PeriodicalId":49789,"journal":{"name":"Mutation Research-Reviews in Mutation Research","volume":"787 ","pages":"Article 108374"},"PeriodicalIF":6.4000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.mrrev.2021.108374","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mutation Research-Reviews in Mutation Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1383574221000119","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 18

Abstract

Among cell surface markers, CD44 is considered the main marker for identifying and isolating the cancer stem cells (CSCs) among other cells and has attracted significant attention in a variety of research areas. Many studies have shown the essential roles of CD44 in initiation, metastasis, and tumorigenesis in different types of cancer; however, the validity of CD44 as a therapeutic or diagnostic target has not been fully confirmed in some other studies. Whereas the association of specific single nucleotide polymorphisms (SNPs) in the CD44 gene and related variants with cancer risk have been observed in clinical investigations, the significance of these findings remains controversial. Here, we aimed to provide an up-to-date overview of recent studies on the association of CD44 polymorphisms and its variants with different kinds of cancer to determine whether or not it can be used as an appropriate candidate for cancer tracking.

查看原文本刊更多论文

CD44多态性及其变异，作为癌症调查中不一致的标记

在细胞表面标记物中，CD44被认为是鉴别和分离肿瘤干细胞(cancer stem cells, CSCs)的主要标记物，在各个研究领域受到了广泛关注。许多研究表明，CD44在不同类型癌症的起始、转移和肿瘤发生中发挥重要作用;然而，在其他一些研究中，CD44作为治疗或诊断靶点的有效性尚未得到充分证实。尽管在临床研究中已经观察到CD44基因特异性单核苷酸多态性(snp)和相关变异与癌症风险的关联，但这些发现的意义仍然存在争议。在这里，我们旨在提供关于CD44多态性及其变异与不同类型癌症的关联的最新研究综述，以确定它是否可以用作癌症跟踪的合适候选。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mutation Research-Reviews in Mutation Research 生物-毒理学

CiteScore

12.20

自引率

1.90%

发文量

审稿时长

15.7 weeks

期刊介绍： The subject areas of Reviews in Mutation Research encompass the entire spectrum of the science of mutation research and its applications, with particular emphasis on the relationship between mutation and disease. Thus this section will cover advances in human genome research (including evolving technologies for mutation detection and functional genomics) with applications in clinical genetics, gene therapy and health risk assessment for environmental agents of concern.